December 1, 2016 - By kentuckypostne · 0 Comments
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) institutional sentiment decreased to 1.02 in Q2 2016. Its down -0.25, from 1.27 in 2016Q1. The ratio has worsened, as 116 institutional investors increased or opened new equity positions, while 91 sold and reduced their equity positions in Alnylam Pharmaceuticals Inc. The institutional investors in our partner’s database now have: 72.84 million shares, up from 71.20 million shares in 2016Q1. Also, the number of institutional investors holding Alnylam Pharmaceuticals Inc in their top 10 equity positions was flat from 6 to 6 for the same number . Sold All: 31 Reduced: 60 Increased: 93 New Position: 23.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $3.39 billion. The Firm is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). It currently has negative earnings. The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs).
About 1.45 million shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 35.37% since April 28, 2016 and is downtrending. It has underperformed by 41.30% the S&P500.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on February, 9. They expect $-1.35 earnings per share, down 26.17% or $0.28 from last year’s $-1.07 per share. After $-1.21 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.57% negative EPS growth.
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Rtw Investments Llc holds 15.78% of its portfolio in Alnylam Pharmaceuticals, Inc. for 832,549 shares. 12 West Capital Management Lp owns 700,000 shares or 6.26% of their US portfolio. Moreover, Slate Path Capital Lp has 4.93% invested in the company for 1.14 million shares. The New York-based Fic Capital Inc has invested 4.45% in the stock. Aureus Asset Management Llc, a Massachusetts-based fund reported 164,161 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 1 buying transaction, and 1 sale for $918,262 net activity.
Ratings analysis reveals 57% of Alnylam Pharmaceuticals’s analysts are positive. Out of 14 Wall Street analysts rating Alnylam Pharmaceuticals, 8 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $34 while the high is $184. The stock’s average target of $85.07 is 105.48% above today’s ($41.4) share price. ALNY was included in 31 notes of analysts from August 7, 2015. As per Wednesday, November 30, the company rating was maintained by Chardan Capital Markets. The rating was initiated by Morgan Stanley on Tuesday, August 2 with “Overweight”. The rating was downgraded by JP Morgan on Thursday, October 6 to “Neutral”. Chardan Capital Markets maintained the shares of ALNY in a report on Thursday, October 6 with “Buy” rating. As per Thursday, October 6, the company rating was maintained by Credit Suisse. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Overweight” rating given on Monday, August 31 by Piper Jaffray. Goldman Sachs maintained the shares of ALNY in a report on Thursday, October 6 with “Neutral” rating. The rating was maintained by JP Morgan with “Overweight” on Friday, August 5. Jefferies maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, August 5. Jefferies has “Buy” rating and $86 price target. As per Thursday, October 6, the company rating was maintained by Jefferies.
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
More recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data” on November 04, 2016. Also Fool.com published the news titled: “Why Alnylam Pharmaceuticals, Inc. Took a 47.5% Dive in October” on November 07, 2016. Businesswire.com‘s news article titled: “Alnylam Pharmaceuticals and The Medicines Company Announce Publication of …” with publication date: November 13, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.